Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a mo… Read more
Kiniksa Pharmaceuticals Ltd (KNSA) - Total Liabilities
Latest total liabilities as of September 2025: $176.95 Million USD
Based on the latest financial reports, Kiniksa Pharmaceuticals Ltd (KNSA) has total liabilities worth $176.95 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kiniksa Pharmaceuticals Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Kiniksa Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kiniksa Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Kiniksa Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anhui Great Wall Military Industry Co Ltd
SHG:601606
|
China | CN¥2.20 Billion |
|
Guangdong Dongfang Precision Science & Technology Co Ltd
SHE:002611
|
China | CN¥2.88 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥1.00 Billion |
|
Voltronic Power Technology Corp
TW:6409
|
Taiwan | NT$7.46 Billion |
|
Zhejiang Dingli Mach Co Ltd
SHG:603338
|
China | CN¥5.93 Billion |
|
Skyward Specialty Insurance Group, Inc. Common Stock
NASDAQ:SKWD
|
USA | $3.63 Billion |
|
Sumber Alfaria Trijaya Tbk
JK:AMRT
|
Indonesia | Rp21.40 Trillion |
|
Veritex Holdings Inc
NASDAQ:VBTX
|
USA | $10.88 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Kiniksa Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kiniksa Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kiniksa Pharmaceuticals Ltd (2016–2024)
The table below shows the annual total liabilities of Kiniksa Pharmaceuticals Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $142.12 Million | +62.45% |
| 2023-12-31 | $87.48 Million | +37.72% |
| 2022-12-31 | $63.52 Million | +33.00% |
| 2021-12-31 | $47.76 Million | +27.27% |
| 2020-12-31 | $37.53 Million | +28.92% |
| 2019-12-31 | $29.11 Million | -31.82% |
| 2018-12-31 | $42.70 Million | -68.88% |
| 2017-12-31 | $137.20 Million | +66.91% |
| 2016-12-31 | $82.20 Million | -- |